BioAtla Q3 net loss widens to $15.8 mln
BioAtla's Q3 net loss widened to $15.8 million due to lack of collaboration revenue. R&D expenses decreased from $16.4 million to $9.5 million due to program prioritization and workforce reduction. The company aims to finalize a strategic transaction by year-end. Analysts rate the stock as "buy" with a median price target of $10.00, significantly higher than its current price of $0.69.
)
Overview
- BioAtla Q3 net loss widens to $15.8 mln, driven by absence of collaboration revenue
- R&D expenses decreased due to program prioritization and workforce reduction
- Company in advanced stages to finalize strategic transaction by year-end
Outlook
- BioAtla expects to complete a strategic partnership by year end
Result Drivers
- Research and development (R&D) expenses were $9.5 million for the quarter ended September 30, 2025, compared to $16.4 million for the same quarter in 2024.
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$15.78
Income mln
Q3 $13.79
Operatin mln
g
Expenses
Q3 -$13.79
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 1 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Bioatla Inc is $10.00, about 93.1% above its November 12 closing price of $0.69
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
